AbbVie Inc. (ABBV)
Overview · Option chain · Volatility · Expected-move history · Earnings
Cboe delayed options data · as of 18:33 UTC · Figures derived from the full chain (1,344 contracts, 15 expirations) · IV own-history percentile appears after 60 recorded days (29 so far)
Expected move · Nov 20, 2026 (31 days)
Methodology →Read from option prices: the at-the-money straddle costs this much, so the market is pricing a move of about that size in either direction by this date. It is an estimate of movement, not a prediction of direction.
Options are pricing a move of about ±6.9% (range 269.68–309.83) by Nov 20, 2026. ATM straddle: 20.07 @ strike 290 · ATM IV: 29.7%.
Probability distribution
Model & assumptions →The curve shows where a lognormal model, fed with current implied volatility, puts the range of outcomes at this expiration. Shaded: the expected-move band.
| Level | vs price | P(above)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(below) |
|---|---|---|---|
| 260.78 | -10% | 88.0% | 12.0% |
| 275.27 | -5% | 70.9% | 29.1% |
| 289.75 | -0% | 48.3% | 51.7% |
| 304.24 | +5% | 27.2% | 72.8% |
| 318.73 | +10% | 12.6% | 87.4% |
Model-estimated probabilities of finishing above/below each level at expiration: estimates under stated assumptions, not predictions.
Probability explorer
Drag the slider to any level and see the model-estimated chance the stock finishes above or below it at the selected expiration.
Horizon: Nov 20, 2026 · lognormal model with zero drift: an estimate, not a prediction. Assumptions
Expirations
Open the chain →| Expires | DTEDays to expiration, in calendar days. | Implied move | ATM IV | Open int. |
|---|---|---|---|---|
| Oct 23, 2026 | 3 | ±2.2% | 29.8% | 9,042 |
| Oct 30, 2026 | 10 | ±5.1% | 38.5% | 4,881 |
| Nov 06, 2026 | 17 | ±5.9% | 34.1% | 2,603 |
| Nov 13, 2026 | 24 | ±6.6% | 32.1% | 3,109 |
| Nov 20, 2026 | 31 | ±6.9% | 29.7% | 39.4K |
| Nov 27, 2026 | 38 | ±7.6% | 29.3% | 1,190 |
| Dec 18, 2026 | 59 | ±9.0% | 27.8% | 50.0K |
| Jan 15, 2027 | 87 | ±10.6% | 26.7% | 62.4K |
| Feb 19, 2027 | 122 | ±13.1% | 28.4% | 12.0K |
| Mar 19, 2027 | 150 | ±14.4% | 28.2% | 23.1K |
Open interest by strike · Nov 20
Where option positions are concentrated. Teal bars are calls, red bars are puts; the dashed line is the current price.
Largest open-interest concentrations (all expirations ≤ 60 days): 300 C · 17.3K290 C · 13.6K230 P · 9,607280 C · 6,792240 P · 5,400
IV term structure
Volatility page →At-the-money implied volatility for each expiration. A hump around a date often marks a scheduled event the market is pricing.
When does open interest expire?
Implied vs realized volatility
HV from our stored daily closes (annualized); IV30 interpolated from the chain. Method
Price, last 60 sessions
Daily closes; Financial Modeling Prep.
Track record
Full history →Of 121 recorded snapshot-versus-outcome comparisons so far, the close landed inside the expected range 55.4% of the time.
Past earnings reactions
Avg |reaction| 5.1% · median 5.1% (20 reports). Two-session close-to-close window; definition
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatm
Healthcare · Drug Manufacturers - General · NYSE · Profile: Financial Modeling Prep
Related securities · Healthcare
PFE · IV 26.2%UNH · IV 28.1%MRNA · IV 112.1%HIMS · IV 89.5%LLY · IV 41.6%BMY · IV 34.6%